menu

Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape

Program Information
Recommended

Program Information

Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
RestartResume

Non-small cell lung cancer is characterized by an expanding number of genomic alterations, which is why testing for biomarkers like KRAS G12C may be important. 

  • Sponsored by

  • Overview

    In the current era of cancer care, we’ve come to realize that non-small cell lung cancer is a disease of the genome. And now that advances in genomic profiling have enabled the identification of emerging biomarkers such as KRAS G12C oncologist Dr. Alex Spira and pathologist Dr. John Longshore are here to give us a closer look at the guideline recommendations for biomarker testing as well as best practices for overcoming real-world issues.

    © 2020 Amgen Inc. All rights reserved. USA-510-80117 10/2020

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/6/21